Rising demand for gene and cell therapies drives market growth. Plasmid DNA is a vital component of gene therapy and gene editing processes. It acts as a delivery vehicle for therapeutic genes. Growing applications of plasmid DNA in DNA vaccination, immunotherapy, and cancer treatment also drives market growth. Progress in R&D related to genetic disorders for molecular biological research provides opportunities for market players.
Request a Sample Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/2593
Market Trends
Another key trend gaining traction is focus on technology advancements. This is owing to reduced overhead costs, access to enhanced technologies, and increased production capacity. Investment in technologies such as miniaturized bioreactors yield of high-quality plasmid DNA is gaining traction.
Plasmid DNA Manufacturing Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2022 |
$735.67 million |
|
Estimated Value by 2030 |
$3,733.50 million |
|
Growth Rate |
Poised to grow at a CAGR of 22.5% |
|
Historical Data |
2017–2020 |
|
Forecast Period |
2022–2030 |
|
Forecast Units |
Value (USD Million/Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
By Product Type, By Grade, By Application, By Manufacturing Type, By Development Phase |
|
Geographies Covered |
North America, Europe, Asia Pacific, and Rest of World |
|
Growth Drivers |
• Increasing inorganic strategies such as collaboration by key players in the market to expand product portfolio • The increasing demand for plasmid (pDNA) DNA and increasing research and development activities by key players in the market |
|
Restraints & Challenges |
• The complex manufacturing process of plasmid DNA • The high cost of gene therapy |
Market Opportunities
The viral vectors segment dominated plasmid DNA manufacturing market in 2022. Viral vectors are widely used for gene therapy and DNA vaccination applications. This is due to their high delivery efficiency. Advances in viral engineering technologies have improved the safety and efficacy of viral vectors.
Immediate Delivery Available | Buy This Premium Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2593
The GMP grade plasmid DNA will drive the demand for DNA manufacturing market. GMP grade plasmids are required for clinical and commercial applications. This is owing to increased investments towards developing robust GMP-compliant.
Key Market Takeaways
The global plasmid DNA manufacturing market is anticipated to witness a CAGR of 22.5% during the forecast period. This is owing to the growing demand for plasmid DNA for gene therapy, DNA vaccines, and immunotherapy applications.
On the basis of product type, the viral vectors segment is expected to hold a dominant position. This is owing to its high transduction efficiency.
On the basis of grade, GMP grade plasmid DNA segment is expected to hold a dominant position over the forecast period. This is due to mandatory regulatory requirements for clinical and commercial manufacturing.
By application, the DNA vaccines segment dominated the market in 2023 and is expected to maintain its lead. This is due to DNA vaccine development against various infectious diseases and cancers.
North America is expected to hold a dominant position over the forecast period. This is due to extensive R&D activities and presence of leading market players in the region.
Competitor Insights
Cobra Biologics and Pharmaceutical Services
VGXI Inc.
Kaneka Corporation
Nature technology
Plasmid Factory GmbH & Co.
LakePharma, Inc.
MeiraGTx Limited
Eurofins Genomics
Vigene Biosciences
Luminous Biosciences, LLC
GenScript
GENEWIZ
Creative Biogene
Recent Developments
In October 2022, Ray Therapeutics and Forge Biologics entered into a collaboration. This collaboration aims at producing clinical stage plasmid DNA to support gene therapy program.
In August 2021, INOVIO announced that it had received regulatory authorization from Brazil's ANVISA for DNA vaccine for COVID-19.
Ask For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/2593
Detailed Segmentation:
By Product Type:
- Viral Vectors
- Retroviral
- Adenoviral
- Lentiviral
- Adeno Associates
- Others
- Plasmid DNA
- mRNA
- Others
- Non-viral
- Lipid/Polymer
- Electroporation
- Nanoparticles
- Others
By Grade:
- GMP Grade
- R&D Grade
- Clinical Grade
By Application:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- RNA Vaccines
- Others
By Manufacturing Type:
- Outsourcing
- In-house Manufacturing
By Development Phase:
- Pre-Clinical Therapeutics
- Clinical Therapeutics
- Marketed Therapeutics
By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Find Most Trending Related Reports:
The global biopharmaceutical and biomedicine market is estimated to be valued at US$ 561,375.9 million in 2022 and is expected to exhibit a CAGR of 9.6% during the forecast period (2022-2030).
The global long read sequencing market size is expected to reach US$ 5,142.3 Mn by 2031, from US$ 780 Mn in 2024, exhibiting a compound annual growth rate (CAGR) of 30.9% during the forecast period.
The global DNA nanotechnology market was valued at US$ 4.38 Bn in 2023 and is expected to reach US$ 26.08 Bn by 2031, growing at a compound annual growth rate (CAGR) of 25% from 2024 to 2031.
The global synthetic biology market is estimated to be valued at USD 17.88 Bn in 2024 and is expected to reach USD 73.08 Bn by 2031, growing at a compound annual growth rate (CAGR) of 22.3% from 2024 to 2031.
The global recombinant DNA technology market is estimated to be valued at USD 172.94 Bn in 2024 and is expected to reach USD 327.63 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.6% from 2024 to 2031.
The global Gene Therapy Market, Size, Share, Outlook, and Opportunity Analysis, 2022-2028
The global cell and gene therapy market is estimated to be valued at US$ 22.7 billion in 2023 and is expected to exhibit a CAGR of 28.7% during the forecast period (2023-2030).
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-650-918-5898
UK: +44-020-8133-4027
AUS: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
